Found: 10
Select item for more details and to access through your institution.
Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 5, p. 388, doi. 10.1002/cpdd.121
- By:
- Publication type:
- Article
Interleukin-6 Contributes to Inflammation and Remodeling in a Model of Adenosine Mediated Lung Injury.
- Published in:
- PLoS ONE, 2011, v. 6, n. 7, p. 1, doi. 10.1371/journal.pone.0022667
- By:
- Publication type:
- Article
Collagen II antibody-induced arthritis in Tg1278TNFko mice: optimization of a novel model to assess treatments targeting human TNFα in rheumatoid arthritis.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Efficacy of an Inhaled IL-13 Antibody Fragment in a Model of Chronic Asthma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
- Published in:
- British Journal of Clinical Pharmacology, 2017, v. 83, n. 5, p. 991, doi. 10.1111/bcp.13185
- By:
- Publication type:
- Article
CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.
- Published in:
- Arthritis Research & Therapy, 2015, v. 17, n. 1, p. 1, doi. 10.1186/s13075-015-0757-4
- By:
- Publication type:
- Article
Interleukin 17A and IL-17F Expression and Functional Responses in Rheumatoid Arthritis and Peripheral Spondyloarthritis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. N.PAG, doi. 10.3389/fimmu.2020.01894
- By:
- Publication type:
- Article
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Interleukin (IL)-12 and IL-18 Synergize to Promote MAIT Cell IL-17A and IL-17F Production Independently of IL-23 Signaling.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. N.PAG, doi. 10.3389/fimmu.2020.585134
- By:
- Publication type:
- Article